CION Ameerpet
Rare Cervical Cancer Types · Reviewed by CION Oncologists · NABH Accredited
Small Cell & Neuroendocrine Cervical Cancer — A Rare Type With Its Own Pathway
Neuroendocrine carcinoma of the cervix is rare — a very small minority of cervical cancers — and it does not behave like the common types. It grows quickly and tends to travel early through lymph channels and the bloodstream, which is why treatment guidelines place it on a separate pathway in which systemic chemotherapy is part of the plan from the beginning rather than something held in reserve. If this is the diagnosis on your report, two things follow immediately: the histology needs confirming with the right stains, and the staging work-up needs to be thorough and fast. This page explains both, and what the outlook honestly depends on.
- Treated on its own pathway — NCCN handles neuroendocrine cervical carcinoma separately from the common types
- Systemic treatment starts early — chemotherapy forms part of the plan even when the tumour looks confined
- Confirmation matters — neuroendocrine markers on immunohistochemistry are what settle the diagnosis
- Speed without shortcuts — complete staging first, then a tumour board plan, without weeks lost in between
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What a Neuroendocrine Diagnosis of the Cervix Means
Scattered through the lining of the cervix are neuroendocrine cells — cells that sit at the junction of the nervous and hormonal systems and release signalling molecules. When a cancer arises from them, it is called a neuroendocrine neoplasm, and under the microscope it looks nothing like the common cervical cancers. In the small cell form, the tumour is made up of densely packed cells with very little cytoplasm and a high rate of division.
The name is borrowed from the lung, where small cell carcinoma is far more familiar, and that borrowing is deliberate: the two behave similarly enough that the treatment approach for cervical small cell carcinoma is closer to the lung small cell approach than to the standard cervical cancer approach. This is the reason your care may look different from that of a woman with squamous cell carcinoma of the cervix diagnosed at the same stage, and it is a deliberate choice rather than an inconsistency.
Two things are worth holding onto at this point. First, the diagnosis rests on more than appearance — it needs neuroendocrine markers demonstrated on staining, and that confirmation should be in hand before treatment is decided. Second, rarity is not the same as being untreatable. Neuroendocrine cervical carcinoma is treated with intent to cure in localised disease, and the combination of local and systemic treatment is what makes that possible.
Did You Know? “Neuroendocrine” on a cervical report covers two quite different groups. The WHO classification separates low-grade neuroendocrine tumours, which are indolent and rare in the cervix, from high-grade neuroendocrine carcinomas — the small cell and large cell types — which are the aggressive ones. They are not treated the same way, so the exact wording on your report genuinely matters, and it is a reasonable thing to ask your oncologist to read back to you. Source: WHO Classification of Tumours, Female Genital Tumours, 5th edition (2020).
The Terms on a Neuroendocrine Cervical Report
Six phrases account for most of what appears on these reports. Knowing which one you have is the first practical step.
High grade
Small Cell Neuroendocrine Carcinoma
The commonest neuroendocrine cancer of the cervix. Small, tightly packed cells with scant cytoplasm and a very high rate of division. This is the type that drives the separate, systemic-treatment-led pathway.
High grade
Large Cell Neuroendocrine Carcinoma
Larger cells with more cytoplasm and prominent nucleoli, but the same high-grade, fast-dividing behaviour. It is managed on the same principles as the small cell form, and the two are often discussed together for that reason.
Low grade
Neuroendocrine Tumour (NET, Grade 1 or 2)
The indolent end of the spectrum, very rare in the cervix, sometimes still called carcinoid. It behaves quite differently from the high-grade carcinomas and does not belong on the same treatment pathway.
Mixed
Carcinoma With a Neuroendocrine Component
A tumour that is mostly squamous or glandular but contains neuroendocrine cancer as well. The neuroendocrine part directs management even when it makes up a minority of the tumour — which is why it is looked for in mixed cervical tumours.
How it is proven
Synaptophysin, Chromogranin, INSM1, CD56
The neuroendocrine markers. Staining positive for these, alongside a high mitotic count and a high Ki-67 proliferation index, is what converts a microscopic impression into a confirmed diagnosis.
The cause
HPV Association
Most neuroendocrine cervical carcinomas are linked to high-risk HPV, HPV 18 in particular. The behaviour of the tumour is unusual; its cause is not. Screening and vaccination remain relevant to preventing it.
Other uncommon cervical histologies follow the standard pathway rather than this one — see, for example, clear cell cervical cancer, which is rare but is managed with the usual stage-based framework.
Why This Type Is Treated Differently
The reason is not that the cervix behaves differently, but that neuroendocrine cancer does. Five features drive every decision that follows:
- It divides fast. A high mitotic count and a high Ki-67 index mean the tumour can change measurably over weeks. Delay between diagnosis and the start of treatment costs more here than it does in slower histologies.
- It travels early. Spread through lymph channels and the bloodstream can happen while the primary tumour is still small, which is why a clinically early stage is not taken as reassurance on its own.
- Local treatment alone is usually not enough. Surgery or radiation deals with the cervix and pelvis. Because microscopic disease may already be elsewhere, systemic chemotherapy is combined with local treatment rather than kept for later.
- The staging work-up is wider. Alongside MRI and PET-CT, imaging of the brain is often included, because this histology can spread there and because finding it early changes the plan.
- It responds to chemotherapy. Fast-dividing tumours are often chemo-sensitive, and this one frequently is. Response is usually rapid; the challenge is durability, which is why the whole planned course matters and why surveillance afterwards is close.
An honest word about outlook. Neuroendocrine carcinoma of the cervix has a less favourable prognosis than the common cervical cancers at the same stage, and no one should tell you otherwise. Equally, no one can tell you your outcome from a histology line alone. Stage, whether disease is confined to the pelvis, response to the first phase of treatment and completion of the full plan all shape what happens, and localised disease is treated with the intention of cure. Ask your oncologist for the picture in your case, with your scans in front of them.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
With This Histology, Weeks Matter
Confirmation, staging and a tumour board decision can be completed in days rather than weeks when they are arranged together. All three are available across CION's 7 NABH-accredited Hyderabad locations.
The Work-Up, Step by Step
The cervix is still staged with FIGO 2018 — there is no separate neuroendocrine staging system for this site. What changes is how much is looked at, and how quickly.
Step 1 — Confirm the neuroendocrine diagnosis
Neuroendocrine markers are demonstrated on the biopsy tissue, and the mitotic count and Ki-67 index are reported. This step separates a high-grade carcinoma from a low-grade tumour, and it identifies a neuroendocrine component hidden inside an otherwise conventional carcinoma. Where any doubt remains, the original slides and blocks are re-read before treatment begins.
Step 2 — MRI of the pelvis
MRI defines the size of the tumour, how far it has grown through the cervical wall, and whether it has reached the parametrium, vagina, bladder or rectum. It is what the local stage rests on.
Step 3 — PET-CT of the whole body
Given how readily this histology spreads, whole-body assessment is not a formality. PET-CT looks at pelvic and para-aortic lymph nodes and at distant sites, and its findings frequently change the plan rather than merely confirming it.
Step 4 — Brain imaging where indicated
Because neuroendocrine carcinoma can spread to the brain, imaging of the head is often added to the work-up. It is a precaution rather than an expectation, and it is far better done before treatment starts than discovered afterwards.
Step 5 — Tumour board, quickly
Surgical, radiation and medical oncology decide the sequence together. For a histology this uncommon, that shared decision is more valuable than any single opinion, and NCCN and ESMO both frame rare cervical histologies as multidisciplinary decisions.
How This Differs From the Common Cervical Cancers
A side-by-side view of where the pathways diverge. The left column describes the usual approach for squamous and glandular cervical cancers; the right, what changes for a high-grade neuroendocrine carcinoma.
| Squamous / glandular cervical cancer | High-grade neuroendocrine carcinoma | |
|---|---|---|
| Frequency | Together, the overwhelming majority of cervical cancers | Rare — a very small minority of cases |
| Staging system | The same — FIGO 2018 for carcinoma of the cervix | |
| Treatment algorithm | Single stage-driven pathway shared across the histologies | A separate pathway in the guidelines, led by systemic treatment |
| Role of chemotherapy in early stage | Often not needed if surgery clears the disease | Part of the plan even when the tumour appears confined |
| Staging scans | MRI and PET-CT | MRI and PET-CT, with brain imaging added where indicated |
| Pace of decision-making | Measured; time exists to complete the work-up | Urgent; the work-up is compressed deliberately |
| Surveillance after treatment | Standard follow-up schedule | Closer, because recurrence tends to be early and distant |
For the wider picture of how cervical cancer arises, is screened for and is prevented, start from the cervical cancer overview.
Did You Know? However unusual its behaviour, this cancer has an ordinary cause. Most neuroendocrine carcinomas of the cervix are HPV-associated, with HPV 18 the type most often implicated — the same virus behind the common cervical cancers. That is why cervical screening and HPV vaccination remain relevant to preventing it, and why a diagnosis in the family is a prompt for other women in the household to check that their own screening is up to date. Source: WHO Classification of Tumours, Female Genital Tumours, 5th edition (2020).
How Neuroendocrine Cervical Cancer Is Treated
Treatment is built on a simple principle: deal with the tumour in the pelvis, and deal at the same time with disease that may already have travelled. In practice that means combining local and systemic treatment rather than choosing between them.
Localised disease — combined local and systemic treatment
Depending on the size and stage, the pelvis is treated either by surgery with lymph node assessment or by chemoradiation with brachytherapy. Platinum-based combination chemotherapy of the kind used for small cell carcinoma is given as part of the same overall plan, before or after the local treatment, because microscopic spread is assumed rather than ruled out.
Locally advanced disease — chemoradiation with systemic treatment
External radiation to the pelvis with chemotherapy alongside it, followed by brachytherapy, integrated with a full systemic course. Completing brachytherapy within the planned overall treatment time is as important here as it is in the common cervical cancers.
Metastatic disease — systemic treatment first
Chemotherapy leads, with radiation used to control specific sites such as bone or brain deposits. Immunotherapy may be considered depending on what testing of the tumour shows. The specific regimens are individual decisions and are set out on our cervical cancer treatment in Hyderabad page.
After treatment — closer surveillance
Follow-up is more frequent than for the common histologies, because recurrence, when it happens, tends to happen early and away from the pelvis. Knowing that in advance makes the schedule feel purposeful rather than alarming, and it means any change is picked up while options remain.
Clinical trial participation is worth asking about with a rare histology, since the evidence base is smaller than for the common types and enrolment is one of the ways it grows. Your oncologist can tell you what is open and whether you would be eligible.
Why a Rare Cervical Cancer Belongs With a Full Team
When the histology is uncommon and the tumour moves quickly, coordination is the treatment variable you can actually control.
Marker confirmation before treatment
Tumour board within days, not weeks
MRI, PET-CT and brain imaging in-house
Medical and radiation oncology on site
Brachytherapy planned from day one
45-minute detailed consultation
7 NABH-accredited Hyderabad locations
EMI facility & insurance accepted
4.8 / 5 Google rating
Take The Next Step
Rare Does Not Mean You Wait Longer
If a report has used the word neuroendocrine, the useful next move is a conversation with someone who treats it — this week, with your slides and scans in the room.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Small Cell & Neuroendocrine Cervical Cancer — Frequently Asked Questions
What is small cell neuroendocrine cervical cancer?
It is a rare, high-grade cancer arising from the neuroendocrine cells scattered through the lining of the cervix, and it makes up only a very small minority of cervical cancers. Under the microscope the cells are small, tightly packed and dividing rapidly. The name is borrowed from small cell carcinoma of the lung because the two behave similarly, and that similarity is why treatment follows a different pathway from the common cervical cancers. The diagnosis is not made on appearance alone — neuroendocrine markers must be demonstrated on immunohistochemistry before the pathway is chosen.
Why is chemotherapy recommended even though my tumour looks early?
Because this histology tends to spread through lymph channels and the bloodstream while the primary tumour is still small. Surgery or radiation deals thoroughly with the cervix and the pelvis, but neither can treat microscopic disease that has already travelled elsewhere. Treatment guidelines therefore combine local treatment with systemic chemotherapy from the outset rather than holding chemotherapy in reserve for a recurrence. It can feel like being over-treated for an early cancer. In this particular histology it is the approach that gives localised disease the best chance of being cleared completely.
What tests confirm a neuroendocrine cervical cancer?
The biopsy tissue is stained for neuroendocrine markers such as synaptophysin, chromogranin, INSM1 and CD56, and the pathologist reports the mitotic count and the Ki-67 proliferation index. Together these confirm neuroendocrine differentiation and separate a high-grade carcinoma from a low-grade neuroendocrine tumour, which behaves quite differently. The same stains are used to detect a neuroendocrine component hidden inside an otherwise conventional cervical carcinoma. Where the picture is not clear-cut, having the original slides and paraffin blocks re-read before treatment starts is a reasonable request and a common one.
Is small cell cervical cancer caused by HPV?
In most cases yes. Neuroendocrine carcinomas of the cervix are usually associated with high-risk human papillomavirus, and HPV 18 is the type most often implicated. So while the tumour behaves quite unlike the common cervical cancers, its underlying cause is the same virus. Two practical points follow. Cervical screening and HPV vaccination remain relevant to preventing this cancer, even though it is rare and screening finds it less readily than it finds squamous precancer. And a diagnosis in the family is a sensible prompt for other women in the household to check that their own screening is up to date.
What is the difference between small cell and large cell neuroendocrine cervical cancer?
The difference is what the cells look like, not how they are managed. In small cell carcinoma the cells are small with very little cytoplasm; in large cell neuroendocrine carcinoma they are larger, with more cytoplasm and prominent nucleoli. Both are high-grade, both divide rapidly and both have the same tendency to spread early, so treatment guidelines group them together and use the same combined local-plus-systemic approach for each. The distinction that genuinely matters on a report is between these high-grade carcinomas and the low-grade neuroendocrine tumours, which are indolent and are managed quite differently.
Medical disclaimer: This page is general health information, reviewed by a CION oncologist. It is not a diagnosis, a stage, a prognosis or a treatment recommendation, and it cannot replace review of your own pathology and imaging by a specialist. Please discuss your report with your treating team before making any decision about treatment.